Meeting
2018 ASCO Annual Meeting
The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
Authors
Steven M. Horwitz
Memorial Sloan Kettering Cancer Center, New York, NY
Steven M. Horwitz , Jasminder Soto , Hagop Youssoufian , Deborah Lloyd , Ngocdiep T. Le
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT03372057
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS7590)
DOI
10.1200/JCO.2018.36.15_suppl.TPS7590
Abstract #
TPS7590
Poster Bd #
222b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.
First Author: Yuqin Song
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2018 ASCO Annual Meeting
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
First Author: Marjorie Glass Zauderer
Poster
2023 ASCO Annual Meeting
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.
First Author: Wenfeng Fang